ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 36

GM-CSF-Producing B Cells: A Novel B Cell Subset Involved in the Pathogenesis of Systemic Sclerosis

Kazuhiko Higashioka1, Yuri Ota1, Tsuyoshi Nakayama1, Koji Mishima1, Masahiro Ayano1, Yasutaka Kimoto2, Hiroki Mitoma1, Mitsuteru Akahoshi1, Yojiro Arinobu1, Koichi Akashi1, Takahiko Horiuchi3 and Hiroaki Niro4, 1Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 4Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cells, cytokines and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a T helper type 2 (Th2)-driven autoimmune disease characterized by vasculopathy and fibrosis. There are still unmet needs in the management of SSc, however B-cell depletion therapy has recently been reported to be effective for this disease. Intriguingly here there is no significant correlation between autoantibody titers and the improvement of clinical symptoms, thus highlighting a novel antibody-independent function of B cells, particularly cytokine production, involved in the pathogenesis of SSc.Granulocyte-macrophage colony-stimulating factor (GM-CSF) exerts a wide range of biological effects mainly on myeloid cells, and B cells has recently been reported as another cellular source of GM-CSF that is induced by a Th2 cytokine IL-4. Given a pathological relevance of Th2 cytokines in SSc and association of GM-CSF with fibrotic processes in various rodent models, in the present study we have sought to elucidate a role of GM-CSF-producing B cells in this disease.

Methods: B cell subsets in peripheral blood from healthy donors and patients with SSc were enriched by cell sorting and subjected to the analysis of GM-CSF transcripts and proteins (intracellular staining and ELISA). The relationship between GM-CSF-producing B cells and the clinical features of SSc was also evaluated. To determine the functional impacts of GM-CSF-producing B cells on myeloid cells, B cells cultured under Th2 conditions were co-cultured with CD14+ monocytes.

Results: Among a panel of CD4+ T cell-derived cytokines, Th2 cytokine IL-4 most significantly induced the generation of GM-CSF-producing memory B cells, while T follicular helper (Tfh) cytokine IL-21 remarkably abrogated this process. Intriguingly TGF-b further potentiated IL-4-induced GM-CSF production in memory B cells. GM-CSF-producing effector B cells were positive for CD30, a distinct phenotype from Ab-producing cells induced by IL-21. GM-CSF production in B cells from patients with SSc was more pronounced than that from healthy donors. This trend was also observed in both naïve and memory B cell subsets. A subpopulation of SSc patients with the diffuse type and concomitant IP, in particular, represented enhanced GM-CSF production in memory B cells. Moreover, B cells cultured under Th2 conditions along with TGF-b facilitated the differentiation from CD14+ monocytes to DC-SIGN+CD1a+CD14-CD86+ cells, a novel DC subset previously reported in skin of SSc patients and SSc model mice.

Conclusion: Together, these findings suggest that GM-CSF-producing effector B cells is a novel B cell subset and play a critical role in the pathogenesis of SSc by Ab-independent mechanisms.


Disclosure: K. Higashioka, None; Y. Ota, None; T. Nakayama, None; K. Mishima, None; M. Ayano, None; Y. Kimoto, None; H. Mitoma, None; M. Akahoshi, None; Y. Arinobu, None; K. Akashi, None; T. Horiuchi, None; H. Niro, None.

To cite this abstract in AMA style:

Higashioka K, Ota Y, Nakayama T, Mishima K, Ayano M, Kimoto Y, Mitoma H, Akahoshi M, Arinobu Y, Akashi K, Horiuchi T, Niro H. GM-CSF-Producing B Cells: A Novel B Cell Subset Involved in the Pathogenesis of Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/gm-csf-producing-b-cells-a-novel-b-cell-subset-involved-in-the-pathogenesis-of-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gm-csf-producing-b-cells-a-novel-b-cell-subset-involved-in-the-pathogenesis-of-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology